Antibody-based therapeutics to watch in 2011

References

• Reichert JM. Metrics for antibody therapeutics development. MAbs 2010; 2:695 - 700
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2010. MAbs 2010; 2:84 - 100
   PubMed Web of Science ®Google Scholar
• Linke R, Klein A, Seimetz D. Catumaxomab: Clinical development and future directions. MAbs 2010; 2:129 - 136
   PubMed Web of Science ®Google Scholar
• Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs 2009; 1:41 - 48
   PubMed Web of Science ®Google Scholar
• Rider DA, Havenith CEG, de Ridder R, Schuurman J, Favre C, Cooper JC, et al. A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res 2007; 67:9945 - 9953
   PubMed Web of Science ®Google Scholar
• Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010; 70:273 - 286
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E, Gniadecki R, Iversen L, Osterborg A, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007; 109:4655 - 4662
   PubMed Web of Science ®Google Scholar
• Umana P, Mössner E, Brünker P, Unsin G, Püntener U, Suter T, et al. Novel 3rd generation humanized Type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. Blood 2006; 108:229
   Google Scholar
• Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115:4393 - 4402
   PubMed Web of Science ®Google Scholar
• Salles GA, Morschhauser F, Cartron G, Lamy T, Milpied NJ, Thieblemont C, et al. A Phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Am Soc Hemotol Ann Meeting 2008; 234 http://ash.confex.com/ash/2008/webprogram/Paper8190.html
   Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102:1458 - 1465
   PubMed Web of Science ®Google Scholar
• Younes A, Forero-Torres A, Bartlett NL, Leonard JP, Lynch C, Kennedy DA, et al. Multiple complete responses in a Phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. Am Soc Hematol Ann Meeting 2008; 1006 http://ash.confex.com/ash/2008/webprogram/Paper8532.html
   Google Scholar
• Bartlett N, Forero-Torres A, Rosenblatt J, Fanale M, Horning SJ, Thompson S, et al. Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol 2009; 27:8500 www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID= 65&abstractID=33524
   Google Scholar
• Bartlett N, Grove LE, Kennedy DA, Sievers EL, Forero-Torres A. Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series. J Clin Oncol 2010; 28:8062 www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID= 74&abstractID=50913
   Google Scholar
• Seattle Genetics September 27, 2010; press release. Seattle Genetics and Millennium announce positive top-line brentuximab vedotin (SGN-35) data from pivotal trial in relapsed and refractory Hodgkin lymphoma. http://investor.seagen.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=1474836&highlight=
   Google Scholar
• O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110:2614 - 2627
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther 2010; 3:15 - 25
   PubMed Web of Science ®Google Scholar
• Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol 2010; 28:3485 - 3490
   PubMed Web of Science ®Google Scholar
• Ralph C, Elkord E, Burt DJ, O'Dwyer JF, Austin EB, Stern PL, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res 2010; 16:1662 - 1672
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res 2010; 16:1042 - 1048
   PubMed Web of Science ®Google Scholar
• Ribas A, Hauschild A, Kefford R, Punt CJ, Haanen JB, Marmol M, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008; 26:9011 http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/LBA9011
   Google Scholar
• Kuenen B, Witteveen PO, Ruijter R, Giaccone G, Dontabhaktuni A, Fox F, et al. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies. Clin Cancer Res 2010; 16:1915 - 1923
   PubMed Web of Science ®Google Scholar
• Tabernero J, Sastre Valera J, Delaunoit T, Cervantes A, Hendlisz A, Youssoufian H, et al. A phase II multicenter study evaluating the efficacy and safety of IMC-11F8, a recombinant human IgG1 anti-epidermal growth factor receptor (EGFR) monoclonal antibody (Mab), combined with 5-FU/FA and oxaliplatin (mFOLFOX-6) as first-line therapy. J Clin Oncol 2008; 26:4066
   Web of Science ®Google Scholar
• Nair P, Melarkoda R, Rajkumar D, Montero E. CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction. Clin Exp Immunol 2010; 162:116 - 130
   PubMed Web of Science ®Google Scholar
• Anand A, Assudani D, Nair P, Krishnamurthy S, Deodhar S, Arumugam M, et al. Safety, efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic psoriasis—results from a randomized phase II trial. J Immunol 2010; 184:96
   Web of Science ®Google Scholar
• Radin A, Mellis S, Jasson M, Nadler D, Belomedtnov P, Wu R, et al. Safety and effects on markers of inflammation of subcutaneously administered REGN88/SAR153191 (REGN88), an interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis: findings from Phase I studies. Ann Rheum Dis 2010; 69:99
   Google Scholar
• Samson CM, Foster CS, Kim R, Falk N, Chu DS, Callanan D, et al. An open-label proof-of concept study to assess the efficacy of AIN457 in patients with noninfectious uveitis. Assoc for Res in Vision and Ophthalmology (ARVO) annual meeting 2010; 2917
   Google Scholar
• Forsberg G, Skartved NJ, Wallén-Ohman M, Nyhlén HC, Behm K, Hedlund G, et al. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity. J Immunother 2010; 33:492 - 499
   PubMed Web of Science ®Google Scholar
• Siebels M, Rohrmann K, Oberneder R, Stahler M, Haseke N, Beck J, et al. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX(R)) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol 2010; http://dx.doi.org/10.1007/s00345-010-0570-2
   PubMed Web of Science ®Google Scholar
• Machiels JH, Subramanian S, Ruzsa A, Repassy G, Lifrenko I, Flygare A, et al. An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE). J Clin Oncol 2010; 28:5506 http://meeting.ascopubs.org/cgi/content/abstract/28/18_suppl/LBA5506
   Web of Science ®Google Scholar
• Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, et al. Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor Alpha, in Epithelial Ovarian Cancer: A Phase I Study. Clin Cancer Res 2010; http://clincancerres.aacrjournals.org/content/early/2010/09/18/1078-0432.CCR-10-0700 http://dx.doi.org/10.1158/1078-0432.CCR-10-0700
   PubMed Web of Science ®Google Scholar
• White AJ, Coleman RL, Armstrong DK, Glenn D, Bicher A, Richards DA, et al. Efficacy and safety of farletuzumab, a humanized monoclonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study. J Clin Oncol 2010; 28:5001 http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/5001
   Web of Science ®Google Scholar
• Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698 - 2704
   PubMed Web of Science ®Google Scholar
• Roche. Investor Science Conference Call www.roche.com/irp091214.pdf
   Google Scholar
• Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330 - 9336
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28:1138 - 1144
   PubMed Web of Science ®Google Scholar
• Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:1131 - 1137
   PubMed Web of Science ®Google Scholar
• Javle MM, Varadhachary GR, Bhosale P, Ukegbu L, Overman MJ, Shroff RT, et al. Phase I study of MK-0646, a humanized monoclonal antibody against IGF-1R in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced previously untreated pancreatic cancer. Am Soc Clin Oncol annual meeting 2010; 131
   Google Scholar
• Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Bhatia S, et al. Phase II study of IMC-1121B in patients with metastatic renal cancer (mRCC) following VEGFR-2 tyrosine kinase inhibitor (TKI) therapy (IMCL CP12-0605/NCT00515697). Am Soc Clin Oncol annual meeting 2010; 326 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abstractID=30312
   Google Scholar
• Feagan B, Leach T, Milch C, Parikh A, Fox I. Emerging Safety Profile of Vedolizumab: A novel, selective Integrin Inhibitor for the treatment of IBD. Gastroenterol Hepatol 2010; 6:25 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886462
   Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598 - 2608
   PubMed Web of Science ®Google Scholar
• Hale G, Rebello P, Al-Bakir I, Bolam E, Wiczling P, Jusko WJ, et al. Pharmacokinetics and antibody responses to the CD3 antibody otelixizumab used in the treatment of Type 1 diabetes. J Clin Pharmacol 2010; http://dx.doi.org/10.1177/0091270009356299
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53:614 - 623
   PubMed Web of Science ®Google Scholar
• Wallance D, Kalunian K, Petri M, Strand V, Kilgallen B, Barry A, et al. Epratuzumab demonstrates clinically meaningful improvements in patients with moderate to severe systemic lupus erythematosus (SLE): results from EMBLEMTM, a Phase IIb study 9th International Congress on Systemic Lupus Erythematosus dgrh.de/fileadmin/media/abstracts/K10-VK.23.pdf
   Google Scholar
• Cephalon news release. Cephalon exercises its option to acquire Ception Therapeutics; Cephalon delivers positive results from a Phase II study of CINQUIL in adult eosinophilic asthma 2010; 2 23 http://investors.cephalon.com/phoenix.zhtml?c=81709&p=irol-newsArticle&ID=1394042&highlight
   Google Scholar
• Cephalon news release. Ception Therapeutics and Cephalon provide initial results of a Phase IIb/III study of CINQUIL in pediatric eosinophilic esophagitis 2009; 11 23 http://investors.cephalon.com/phoenix.zhtml?c=81709&p=irol-newsArticle&ID=1358335&highlight
   Google Scholar
• Mould DR, Weisman LE, Bloom B, Eyal F, Polak M, Fretz J, et al. Predicted and measured pagibaximab serum levels in high-risk neonates 2010; Pediatric Academic Societies and European Society for Pediatric Infectious Diseases meeting http://www.biosynexus.com/phase2b-3.html
   Google Scholar
• Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, Paul SM, et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 2010; 33:67 - 73
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009; 73:2061 - 2070
   PubMed Web of Science ®Google Scholar
• Alzheimer's Association news release. Four New Research Studies Describe Experimental Immunotherapies for Alzheimer's 2010; 7 13 http://www.alz.org/icad/2010_release_four_071310_1230pm.asp
   Google Scholar
• Human Genome Sciences web site http://www.hgsi.com/belimumab.html
   Google Scholar
• Human Genome Sciences and GlaxoSmithKline joint press release. Human Genome Sciences and GlaxoSmithKline announce presentation at EULAR of BLISS-52 Phase 3 study results for BENLYSTA (belimumab) 2010; 6 17 http://www.hgsi.com/latest/human-genome-sciences-and-glaxosmithkline-announce-full-presentation-at-eular-of-bliss-76-phase-3-study-results-for-benlysta-in-systemic-lupus
   Google Scholar
• Human Genome Sciences and GlaxoSmithKline joint press release. Human Genome Sciences and GlaxoSmithKline announce full presentation at EULAR of BLISS-76 Phase 3 study results for BENLYSTA in systemic lupus erythematosus 2010; 6 17 http://www.hgsi.com/latest/human-genome-sciences-and-glaxosmithkline-announce-presentation-at-eular-of-bliss-52-phase-3-sle-study-results-for-benlysta-belim-3.html
   Google Scholar
• Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155 - 164
   PubMed Web of Science ®Google Scholar
• O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 2:1712 - 1717
   Web of Science ®Google Scholar
• Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2010; http://dx.doi.org/10.1007/s10637-009-9376-8
   Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 723
   PubMed Web of Science ®Google Scholar
• Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007; 7:715 - 725
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 2010; 184:1968 - 1976
   PubMed Web of Science ®Google Scholar
• Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010; 28:207 - 214
   PubMed Web of Science ®Google Scholar
• Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, et al. Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial. Urology 2010; 76:923 - 926
   PubMed Web of Science ®Google Scholar
• Townsley C, Hirte H, Hoskins P, Buckanovich R, Mackay H, Welch S, et al. A phase II study of aflibercept (VEGF trap) in recurrent or metastatic gynecologic soft-tissue sarcomas: A study of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 2009; 27:15 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30606
   Web of Science ®Google Scholar
• Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, et al. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol 2010; 5:1054 - 1059
   PubMed Web of Science ®Google Scholar
• Sherman EJ, Ho AL, Haque S, Ghossein RA, Lisa DM, Schöder H, et al. A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine-refractory, positron emission tomography (PET) positive thyroid carcinoma. J Clin Oncol 2010; 28:15 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=53767
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Christensen S, Frankel P, Margolin K, Ruel C, Shipe-Spotloe J, et al. Phase II study of aflibercept (VEGF trap) in recurrent inoperable stage III or stage IV melanoma of cutaneous or ocular origin. J Clin Oncol 2009; 27:15 www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31942
   Web of Science ®Google Scholar
• De Groot JF, Wen PY, Lamborn K, Chang S, Cloughesy TF, Chen AP, et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide-resistant glioblastoma: NABTC 0601. J Clin Oncol 2008; 26:2020 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=32708
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009; 116:2141 - 2148
   PubMed Web of Science ®Google Scholar
• Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004; 6:507 - 516
   PubMed Web of Science ®Google Scholar
• 2010 Clinicaltrials.gov. I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT01042379?term=NCT01042379&rank=1.
   Google Scholar
• Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol 2009; 27:3557 - 3565
   PubMed Web of Science ®Google Scholar
• Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, et al. Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 2010; 16:3044 - 3056
   PubMed Web of Science ®Google Scholar
• Lu J, Rasmussen E, Navale L, Kuchimanchi M, Hurh E, Karlan BY, et al. Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/pharmacodynamic (PK/PD) modeling to facilitate phase III dose selection. J Clin Oncol 2010; 28:15
   PubMed Web of Science ®Google Scholar
• Karlan BY, Oza AM, Hansen VL, Richardson GE, Provencher DM, Ghatage P, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol 2010; 28:15
   PubMed Web of Science ®Google Scholar
• Ahmed S, Anolik JH. B-cell biology and related therapies in systemic lupus erythematosus. Rheum Dis Clin North Am 2010; 36:109 - 130
   PubMed Web of Science ®Google Scholar
• Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010; 12:48
   PubMed Web of Science ®Google Scholar
• Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007; 56:4142 - 4150
   PubMed Web of Science ®Google Scholar
• Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009; 18:547 - 555
   PubMed Web of Science ®Google Scholar
• Nestorov I, Papasouliotis O, Pena Rossi C, Munafo A. Pharmacokinetics and immunoglobulin response of subcutaneous and intravenous atacicept in patients with systemic lupus erythematosus. J Pharm Sci 2010; 99:524 - 538
   PubMed Web of Science ®Google Scholar
• Pierce G. Fusion protein technology-potential treatment for hemophilia. (1) Recombinant Factor VIII-Fc development program; (2) Recombinant Factor IX-Fc development program World Federation of Hemophilia Global Forum September 26, 2009
   Google Scholar
• Swedish Orphan Biovitrum news release. Biogen Idec and Swedish Orphan Biovitrum Announce Decision to Advance Long-Lasting Hemophilia A Therapy into a Registrational Trial 2010; www.biovitrum.com/PageFiles/354/FVIIIFc_20100709.pdf
   Google Scholar
• Peters RT, Low SC, Kamphaus GD, Dumont JA, Amari JV, Lu Q. Prolonged activity of factor IX as a monomeric Fc fusion protein. Blood 2010; 115:2057 - 2064
   PubMed Web of Science ®Google Scholar
• Swedish Orphan Biovitrum news release. Biogen Idec and Swedish Orphan Biovitrum Present Data on Long-Lasting Hemophilia B Therapy at the World Federation of Hemophilia Congress 2010; www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1446254
   Google Scholar